T. Rowe Price Investment Management
PCVX icon

T. Rowe Price Investment Management’s Vaxcyte PCVX Stock Holding History

T. Rowe Price Investment Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$710M Buy
12,207,450
+81,433
+0.7% +$4.42M 0.47% 47
2026
Q1 		$705M Buy
12,126,017
+829,684
+7% +$45M 0.49% 53
2025
Q4 		$521M Buy
11,296,333
+2,981,038
+36% +$133M 0.33% 79
2025
Q3 		$300M Buy
8,315,295
+2,314,171
+39% +$76.7M 0.18% 129
2025
Q2 		$195M Buy
6,001,124
+3,298,433
+122% +$108M 0.12% 181
2025
Q1 		$102M Sell
2,702,691
-158,026
-6% -$12.6M 0.07% 276
2024
Q4 		$234M Sell
2,860,717
-1,193,111
-29% -$118M 0.14% 158
2024
Q3 		$463M Buy
4,053,828
+31,239
+0.8% +$2.82M 0.28% 95
2024
Q2 		$304M Buy
4,022,589
+469,622
+13% +$32M 0.19% 129
2024
Q1 		$243M Buy
3,552,967
+2,306,926
+185% +$160M 0.15% 163
2023
Q4 		$78.3M Buy
1,246,041
+41,413
+3% +$2.15M 0.05% 316
2023
Q3 		$61.4M Buy
1,204,628
+61,710
+5% +$3.04M 0.04% 338
2023
Q2 		$57.1M Buy
1,142,918
+409,011
+56% +$19.4M 0.04% 360
2023
Q1 		$27.5M Buy
733,907
+222,471
+43% +$9.44M 0.02% 438
2022
Q4 		$24.5M Buy
+511,436
New +$20.1M 0.02% 438

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management's PCVX Position: Q2 2026 in Review

T. Rowe Price Investment Management increased its Vaxcyte (PCVX) stake by 0.67% in Q2 2026, buying an estimated $4.42M and bringing the position to 12,207,450 shares worth $710M. The position accounts for 0.47% of the portfolio, ranked #47.

T. Rowe Price Investment Management first reported a position in PCVX in Q4 2022 and has held it in 15 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • T. Rowe Price Investment Management held 12,207,450 shares of Vaxcyte worth $710M as of Q2 2026.
  • T. Rowe Price Investment Management bought 81,433 Vaxcyte shares in Q2 2026, an estimated $4.42M.
  • Vaxcyte made up 0.47% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #47 holding.
  • T. Rowe Price Investment Management first reported a position in Vaxcyte in Q4 2022 and has held it in 15 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.